Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.
IPO Year: 2014
Exchange: NYSE
Website: nevro.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $4.50 → $5.85 | Underperform → Hold | Jefferies |
| 2/7/2025 | $6.00 → $5.85 | Neutral → Overweight | Piper Sandler |
| 12/3/2024 | $5.00 | Equal Weight | Wells Fargo |
| 12/2/2024 | $9.00 → $4.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/9/2024 | Sell → Neutral | Citigroup | |
| 8/8/2024 | Underperform → Peer Perform | Wolfe Research | |
| 8/7/2024 | Mkt Outperform → Mkt Perform | JMP Securities | |
| 8/7/2024 | Neutral → Underweight | JP Morgan | |
| 8/7/2024 | $13.00 → $5.50 | Equal Weight → Underweight | Wells Fargo |
| 5/22/2024 | $13.50 → $9.00 | Neutral → Sell | Citigroup |
Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously
Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously
Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00
Morgan Stanley downgraded Nevro from Equal-Weight to Underweight and set a new price target of $4.00 from $9.00 previously
Citigroup upgraded Nevro from Sell to Neutral
Wolfe Research upgraded Nevro from Underperform to Peer Perform
JMP Securities downgraded Nevro from Mkt Outperform to Mkt Perform
JP Morgan downgraded Nevro from Neutral to Underweight
Wells Fargo downgraded Nevro from Equal Weight to Underweight and set a new price target of $5.50 from $13.00 previously
Citigroup downgraded Nevro from Neutral to Sell and set a new price target of $9.00 from $13.50 previously
15-12G - NEVRO CORP (0001444380) (Filer)
EFFECT - NEVRO CORP (0001444380) (Filer)
SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)
S-8 POS - NEVRO CORP (0001444380) (Filer)